Direct medical costs unequivocally related to diabetes in Italian specialized centers

European Journal of Health Economics

Volumn 5, Issue 1, 2004, Pages 15-21

  Garattini, Livio ^a   Chiaffarino, Francesca ^a   Cornago, Dante ^a   Coscelli, Carlo ^b   Parazzini, Fabio ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Parma Hospital   (Italy)

^c Parma Hospital Trust ^*

Author keywords

Diabetes centers; Direct medical costs; Health care; Italy; Resource utilization

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGE; AGED; ARTICLE; BLINDNESS; CLAUDICATION; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC HYPERTENSION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FOLLOW UP; HEALTH CARE UTILIZATION; HEART DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; ITALY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RESOURCE MANAGEMENT;

ADULT; AGED; AMBULATORY CARE FACILITIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; ITALY; MALE; MIDDLE AGED;

EID: 1542284174     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-003-0188-z     Document Type: Article

References (32)

1. American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296-309
2. Coscelli C, Arcangeli A (1999) Censimento nazionale delle strutture diabetologiche. G Ital Diabetol 19:3133-3138
3. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
4. Garancini MP (1996) II diabete in Italia. Kurtis: Milan
5. Garancini MP, Calori G, Manara E, Izzo A, Ebbli E, Galli L, et al (1993) An Italian population-based study of the prevalence of diabetes: some methodological aspects. Diabetes Metab 19:116-120
6. Garattini L, Giuliani G, Pagano E (1999) A model for calculating costs of hospital wards: an Italian experience. J Manag Med 13:71-82
7. Garattini L, Tediosi F, Ghislandi S, Orzella L, Rossi C (2000) How do Italian pharmacoeconomists evaluate indirect costs? Value Health 3:270-276
8. Garattini L, Tediosi F, Chiaffarino F, Roggeri D, Parazzini F, Coscelli C (2001) The outpatient cost of diabetes care in Italian diabetes centers. Value Health 4:251-257
9. Guo JJ, Gibson JT, Gropper DM, Oswald SL, Barker KN (1998) Empiric investigation on direct cost of illness and healthcare utilization of Medicaid patients with diabetes mellitus. Am J Manag Care 4:1433-1446
10. Hart WM, Espinosa C, Rovira J (1997) A simulation model of the cost of the incidence of IDDM in Spain. Diabetologia 40:312-318
11. Henriksson F, Jonsson B (1998) Diabetes: the cost of illness in Sweden. J Intern Med 244:461-468
12. Henriksson F, Agdarh CD, Berne C, Bolinder J, Lonnqvist F, Stenstrom P, et al (2000) Direct medical costs for patients with type II diabetes in Sweden. J Intern Med 248:387-396
13. Italian Directory of Medicines and Manufacturers (1999) L'Informatore Farmaceutico, 59th edn. OEMF: Milan
14. Jaynes PK, Willis MC, Chan PP (1985) Evaluation of minicolumn chromatographic procedure for the measurement of HbA1c. Clin Biochem 18:32-36
15. Jonsson B (2002) Revealing the cost of type II diabetes in Europe. Diabetologia 45:S5-S12
16. Klonoff DC, Schwartz DM (2000) An economic analysis of interventions for diabetes. Diabetes Care 23:390-404
17. Kruskal WH, Wallis WA (1952) Use of ranks in one criterion variance analysis. J Am Stat Assoc 47:583-621
18. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G (2003) The costs of type 2 diabetes in Italy. A CODE 2 Sub-Study. Treatments in Endocrinology 2:121-133
19. Muggeo M, Tosi F (1994) Note di epidemiologia del diabete in Italia e nel Veneto. Diabete 2:9-13
20. Nicolucci A, Scorpiglione N, Belfiglio M, Carinci F, Cavaliere D, el-Shazly M, et al (1997) Patterns of care of an Italian diabetic population. Diabet Med 14:158-166
21. Norlund A, Apelqvist J, Bitzen PO, Nyberg P, Schersten B (2001) Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med 250:57-65
22. Pagano E, Brunetti M, Tediosi F, Garattini L (1999) Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics 15:583-595
23. Roggeri D, Garattini L (2000) I costi dei centri diabetologici in Italia. G Ital DM 20:41-44
24. Rubin RJ, Altman WM, Mendelson DN (1994) Health care expenditures for people with diabetes mellitus in 1992. J Clin Endocrinol Metab 78:809A-809F
25. Songer T (1992) The economic costs of NIDDM. Diabetes Metab Rev 8:389-404
26. Taroni F (1996) DRG/ROD e nuovo sistema di finanziamento degli ospedali. Pensiero Scientifico: Rome
27. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
28. Verlato G, Muggeo M, Bonora E, Corbellini M, Bressan F, de Marco R (1996) Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study. Diabetes Care 19:211-213
29. Verrillo A, De Teresa A, La Rocca S, Giarrusso PC (1985) Prevalence of diabetes mellitus and impaired glucose tolerance in a rural area of Italy. Diabetes Res 2:301-306
30. Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of type II diabetes. Diabetologia 45:S13-S17
31. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization, Department of Noncommunicable Disease Surveillance: Geneva
32. Zimmet P (2000) Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 247:301-310